Bio­phar­ma bil­lion­aires dom­i­nate Forbes' list of the world's top 10 wealth­i­est health­care ex­ecs — and the pan­dem­ic ...

6 years ago
People

Hos­pi­tals re­port ‘se­vere short­ages’ of Covid-19 tests, HHS sur­vey finds

6 years ago
Coronavirus

Covid-19 roundup: Ex-FDA com­mish Got­tlieb joins Re­pub­li­can gov­er­nor's coro­n­avirus team; Phar­ma ap­proval rat­ings ...

6 years ago
Coronavirus

Gilead gets in on the mi­cro­bio­me game with a $38M pact, up to $1.5B in mile­stones

6 years ago
Deals

An­oth­er pro­tein degra­da­tion biotech emerges, with the promise of a new ap­proach from an old hand

6 years ago
Financing
Startups

Who's do­ing deals in the midst of a crip­pling pan­dem­ic? Here are the top 10 play­ers for March

6 years ago
Deals

Ready to de­clare a de­fin­i­tive come­back in two months, Im­munomedics stops PhI­II ear­ly, re­cruits new CEO

6 years ago
People
R&D

An­oth­er day, an­oth­er boat­load for biotech. Deer­field adds $840M to rush of ven­ture dol­lars

6 years ago
Financing

Small mol­e­cules, bi­o­log­ics and now gene ther­a­pies: Ger­many's Evotec adds an­oth­er feath­er to its R&D cap

6 years ago
R&D

A pair of PhI­II fail­ures spells last rites for Men­lo’s once-promis­ing Mer­ck drug

6 years ago
R&D

Af­ter putting aside a bit­ter le­gal feud, Al­ny­lam and Dicer­na chiefs make nice with an RNAi col­lab­o­ra­tion

6 years ago
Deals
R&D

GSK's Hal Bar­ron buys a $250M stake in George Scan­gos' Vir and makes a bee­line to the clin­ic with Covid-19 an­ti­bod­ies

6 years ago
Deals
R&D

Covid-19 roundup: In­ovio gets FDA green­light to en­ter hu­man tri­als; Trump push­es untest­ed malar­ia drugs again

6 years ago
Coronavirus

Ax­some cel­e­brates mi­graine PhI­II win, shift­ing eyes to­ward a pair of Q4 sub­mis­sions

6 years ago
R&D

Bris­tol My­ers Squibb, Ac­celeron rack up sec­ond OK for Re­blozyl, on­to block­buster sta­tus

6 years ago
Pharma
FDA+

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

6 years ago
People
Special

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

6 years ago
Bioregnum
FDA+

Ramp­ing up glob­al pro­duc­tion of remde­sivir, Gilead CEO Dan O’Day de­tails plans to dis­trib­ute 1.5M dos­es to fight ...

6 years ago
Pharma
Coronavirus

Lil­ly Asia Ven­tures co-leads $100M+ round for Chi­nese biotech and its late-stage lu­pus drug

6 years ago
Financing
China

GSK's asth­ma bi­o­log­ic Nu­cala is one step clos­er to ap­proval in key chron­ic rhi­nos­i­nusi­tis pop­u­la­tion

6 years ago
R&D

Servi­er bags an an­ti­body spe­cial­ist in its lat­est on­col­o­gy M&A deal with plans to add the plat­form tech

6 years ago
Deals
R&D

GSK vac­cine chief heads for AIDS vac­cine ini­tia­tive; Pfiz­er en­lists Sue Desmond-Hell­mann to its board of di­rec­tors

6 years ago
Peer Review

Ahead of US IPO, Leg­end Biotech adds $150M, top-tier in­vestors to back CAR-T pipeline

6 years ago
Financing
R&D

FDA re­ports short­age of se­da­tion drug used for putting Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+
Coronavirus
First page Previous page 838839840841842843844 Next page Last page
A service from the Financial Times